BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19755985)

  • 1. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
    Kalantari HR
    Br J Cancer; 2009 Oct; 101(7):1222-3; author reply 1224. PubMed ID: 19755985
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
    van der Veldt AA; van den Eertwegh AJ; Hoekman K; Barkhof F; Boven E
    Ann Oncol; 2007 Oct; 18(10):1747-50. PubMed ID: 17890217
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    O'Donnell PH
    BJU Int; 2011 Oct; 108(8):1284-5. PubMed ID: 21418138
    [No Abstract]   [Full Text] [Related]  

  • 4. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.
    Flaig TW; Kim FJ; La Rosa FG; Breaker K; Schoen J; Russ PD
    Invest New Drugs; 2009 Feb; 27(1):83-7. PubMed ID: 18563296
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
    van der Veldt AA; Boven E; Helgason HH; van Wouwe M; Berkhof J; de Gast G; Mallo H; Tillier CN; van den Eertwegh AJ; Haanen JB
    Br J Cancer; 2008 Jul; 99(2):259-65. PubMed ID: 18594533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertension as a predictive factor of Sunitinib activity.
    Rixe O; Billemont B; Izzedine H
    Ann Oncol; 2007 Jun; 18(6):1117. PubMed ID: 17586751
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sunitinib-induced pyoderma gangrenosum].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute cardiac failure after sunitinib.
    Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
    Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
    [No Abstract]   [Full Text] [Related]  

  • 9. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
    Al Enazi MM; Kadry R; Mitwali H
    J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
    Yıldız I; Varol U; Şen F; Kılıç L
    Anadolu Kardiyol Derg; 2014 Nov; 14(7):654-6. PubMed ID: 25163084
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    van den Meiracker AH; Danser AH; Sleijfer S; Kappers MH
    J Natl Cancer Inst; 2011 Oct; 103(20):1557; author reply 1558. PubMed ID: 21862728
    [No Abstract]   [Full Text] [Related]  

  • 13. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
    Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
    J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
    J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
    [No Abstract]   [Full Text] [Related]  

  • 15. Sunitinib-induced thyrotoxicosis.
    Piñar D; Boix E; Meana JA; Herrero J
    J Endocrinol Invest; 2009 Dec; 32(11):941-2. PubMed ID: 19636224
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Garfield DH; Hercbergs A; Davis PJ
    J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
    Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
    Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of sunitinib in hemodialysis.
    Izzedine H; Etienne-Grimaldi MC; Renée N; Vignot S; Milano G
    Ann Oncol; 2009 Jan; 20(1):190-2. PubMed ID: 18801884
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
    Daniels GH
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
    [No Abstract]   [Full Text] [Related]  

  • 20. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.
    Kim HS; Hong MH; Kim K; Shin SJ; Ahn JB; Jeung HC; Chung HC; Koh Y; Lee SH; Bang YJ; Rha SY
    Oncology; 2011; 80(5-6):395-405. PubMed ID: 21829041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.